ClinicalTrials.gg
RecruitingNCT05888389Updated Apr 22, 2024

Nerve Block Anesthesia Combined With Sedative Anesthesia Versus General Anesthesia in Surgery for CSDH

An interventional study of Cranial Nerve Block Anesthesia Combined With Sedative Anesthesia and General Anesthesia in Chronic Subdural Hematoma and Anesthesia, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 17 studies in Hematoma, Subdural, Chronic with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Hematoma, Subdural, Chronic · China.

Planned enrollment
9th of 15
190 · median 200
Started
2024
with 2 others
No phase
12 of 17
7 open now
Registered
10th of 17
by date
Lead sponsor
6 of 17
Beijing Tiantan Hospital

Among the 17 studies in Hematoma, Subdural, Chronic with a site in China, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 10th registered.

Hematoma, Subdural, Chronic

112 studies on the registry are indexed under Hematoma, Subdural, Chronic; 49 are open to participants now.

This study's planned enrollment of 190 is close to the median of 185 across 86 interventional studies indexed under Hematoma, Subdural, Chronic.

Browse Hematoma, Subdural, Chronic studies →

Open to participants now

9 of the 17 studies in Hematoma, Subdural, Chronic with a site in China are open now.

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 35 Hematoma, Subdural, Chronic studies recruiting now, 26 (74%) set no upper age limit and 1 (3%) stop at 75 or younger; 1 take children under 18; 1 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →
Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hematoma, Subdural, Chronic with a site in China, or all of them as a file.
02

Study summary

A prospective, multicenter, randomized controlled trial is designed to evaluate the safety of nerve block anesthesia combined with sedative anesthesia versus general anesthesia during burr hole craniostomy with drainage for chronic subdural hematoma.

Read the detailed description

This is a prospective, multi-centre, randomised, controlled, single-blinded, non-inferiority trial. Patients with chronic subdural hematoma undergoing burr-hole drainage will be randomly allocated to receive either the cranial nerve block with dexmedetomidine sedation or general anaesthesia. Patients in the cranial nerve block with dexmedetomidine sedation group will receive cranial nerve block with 0.5% ropivacaine and 1% lidocaine mixture according to incision, combined with dexmedetomidine infusion at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5 to 1ug/kg/h until the end of the operation. Patients in the general anaesthesia group will be induced with propofol or etomidate, sufentanil, rocuronium or cis-atracurium and be maintained with total intravenous anaesthesia. The primary outcome is the incidence of intraoperative limb movement. Secondary outcomes include postoperative delirium within five days after surgery, anaesthesia conversion, postoperative neurological function, intraoperative awareness, and recurrence rate of hematoma within 6 months after surgery.

03

Conditions studied

  • Chronic Subdural Hematoma
  • Anesthesia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic subdural hematoma with preoperative neurological dysfunction for burr hole drainage;
  • Age beween 18 to 80
  • Chronic subdural hematoma verified on cranial computed tomography or magnetic resonance imaging with hematoma thickness >1.0cm or midline shift >1.0 cm.
  • Written obtained

Exclusion criteria

Exclusion Criteria:

  • Preoperative unconsciousness (Glasgow Coma Scale\<13, or Markwalder Grade 2-4) or cognitive dysfunction (Mini-Cog≤3, or ≤20)
  • Preoperative sensory or motor aphasia
  • Recurrence of hematoma with previous surgery for chronic subdural hematoma.
  • Previous intracranial surgery or with intracranial lesion
  • with severe comorbidity or other organ dysfunction
  • Allergic to anesthetics
  • Severe coagulopathy or high risk of life-threatening bleeding
  • Participating in another research
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
190 participants (estimated)

Study arms

  • Active comparator
    General anesthesia (GA)

    The GA group will receive general anesthesia.

    Procedure: General Anesthesia

  • Experimental
    Cranial nerve block anesthesia combined with sedative anesthesia (CNB-D)

    The CNB-D group will receive cranial nerve block anesthesia combined with sedative anesthesia

    Procedure: Cranial Nerve Block Anesthesia Combined With Sedative Anesthesia

Interventions

  • ProcedureCranial Nerve Block Anesthesia Combined With Sedative Anesthesia

    Patients in the nerve block anesthesia combined with sedative anesthesia group will first receive cranial nerve blocks under standard monitoring. At the same time, intravenous dexmedetomidine infusion is started for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5-1ug/kg/h until the Richmond Agitation-Sedation Scale (RASS) of -3.

  • ProcedureGeneral Anesthesia

    Patients will be induced with propofol or etomidate, sufentanil , rocuronium or cisatracurium .

06

What researchers measure

Primary outcomes

  1. Incidence of intraoperative body movement

    Intraoperative body movement is defined as those likely to interfere with surgical procedures such as bending of hand and/or leg and movement of head.

    Time frame: During the surgery

Secondary outcomes

  1. Neurological function

    Measured using Markwalder Grading Scale and the Modified Rankin Scale. Markwalder Grading Scale ranges from grade 0 to 4, and the Modified Rankin Scale score ranges from 0 to 6.

    Time frame: at discharge and 6 months after operation

  2. Recurrence rate at 6 months after surgery

    Rate of reoperations

    Time frame: From operation up to 6 months postoperatively

  3. Conversion to general anesthesia

    For the nerve block anesthesia combined with sedative anesthesia group, general anesthesia is performed if uncontrolled body movements still exist after opioid and sedative supplement.

    Time frame: During the surgery

  4. Intraoperative awareness

    Measured with the Brice questionnaire. Evaluate Intraoperative awareness through the following 6 questions:1. What is the last thing you remember before going to sleep (please tick one box)?2. What is the first thing you remember after waking up (please tick one box)?3. Do you remember anything between going to sleep and waking up (please tick box)?4. Did you dream during your procedure (please tick box)?5. Were your dreams disturbing to you (please tick box)?6. What was the worst thing about your operation (please tick box)?

    Time frame: 1 day after surgery

  5. Postoperative delirium

    POD will be assessed twice a day (before 09:00 and after 16:00) using the Richmond Agitation-Sedation Scale, the Confusion Assessment Method for Intensive Care Unit (CAM-ICU), and the 3- Minute Diagnostic Interview for CAM (3D-CAM).

    Time frame: 1-5 days after surgery

07

Study locations

1 of 1 sites recruiting
  • Tiantan Hospital, Capital Medical University
    Beijing, Beijing 100050, China
    Recruiting
08

References and documents

Publications

  • Wong HM, Woo XL, Goh CH, Chee PHC, Adenan AH, Tan PCS, Wong ASH. Chronic Subdural Hematoma Drainage Under Local Anesthesia with Sedation versus General Anesthesia and Its Outcome. World Neurosurg. 2022 Jan;157:e276-e285. doi: 10.1016/j.wneu.2021.10.074. Epub 2021 Oct 11. PubMed 34648987 ↗
  • Ashry A, Al-Shami H, Gamal M, Salah AM. Local anesthesia versus general anesthesia for evacuation of chronic subdural hematoma in elderly patients above 70 years old. Surg Neurol Int. 2022 Jan 12;13:13. doi: 10.25259/SNI_425_2021. eCollection 2022. PubMed 35127213 ↗
  • Liu HY, Yang LL, Dai XY, Li ZP. Local anesthesia with sedation and general anesthesia for the treatment of chronic subdural hematoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1625-1631. doi: 10.26355/eurrev_202203_28230. PubMed 35302209 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2025, 14 months after the start.

Of 44 interventional studies with no phase under Hematoma, Subdural, Chronic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2023
First posted
Jun 5, 2023
StartActual
Apr 1, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05888389
Responsible party
Weiming Liu (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Jun 5, 2023
Start date
Apr 1, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 22, 2024

Study contacts

Shu Li, M.D.
Contact
lishu@bjtth.org
+8601059976658
Liang Wu, M.D.
Contact
jasewl@sina.com
+8601059975450
Weiming Liu, M.D.
principal investigator · Beijing Tiantan Hospital
Yuming Peng, M.D.
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion